Use of olokizumab in giant cell arteritis with rapidly progressive ischemic optic neuropathy (clinical case)

We present a clinical case of giant cell arteritis (GCA) with ophthalmic manifestations (anterior ischemic optic neuropathy) successfully treated with the direct interleukin-6 inhibitor olokizumab in combination with glucocorticoids. This case demonstrates the efficacy of early initiation of biologic drugs for rapid control of inflammatory activity and prevention of irreversible vision loss in GCA.

1. Alieva AM, Baikova IE, Teplova NV, et al. A clinical case of early diagnosis of giant cell arteritis (Horton's disease) in the practice of a therapist. Terapiya. 2023;9(10):132-138. (In Russ.).

2. Meshkov AD, Maslyanskii AL, Bulanov NM, et al. The use of olokizumab in the treatment of polymyalgia rheumatica and giant cell arteritis: A series of observations. Nauchnoprakticheskaya revmatologiya. 2024;62(4): 431-434. (In Russ.).

3. Paroli M, Caccavale R, Accapezzato D. Giant Cell Arteritis: Advances in Understanding Pathogenesis and Implications for Clinical Practice. Cells. 2024 Jan 31;13(3):267. doi: 10.3390/cells13030267.

4. Estrada P, Narvaez J, Moya P, et al. Clinical Phenotypes of Giant Cell Arteritis: Insights into Complications and Survival Outcomes. Eur J Rheumatol. 2024 Sep 5;11(2): 33-38. doi: 10.5152/eurjrheum.2024.23065.

5. Buttgereit F, Matteson EL, Dejaco C. Polymyalgia Rheumatica and Giant Cell Arteritis. JAMA. 2020 Sep 8;324(10):993-994. doi: 10.1001/jama.2020.10155.

6. De Simone L, Marvisi C, Ricordi C, et al. Interdisciplinary approach in the management of visual loss in giant cell arteritis. Saudi J Ophthalmol. 2024 Nov 18;39(1):14-19. doi: 10.4103/sjopt.sjopt_236_24.

7. Kruszewski AM, Tamhankar MA. Ophthalmic Manifestations of Giant Cell Arteritis. Int Ophthalmol Clin. 2023 Apr 1;63(2):13-23. doi: 10.1097/IIO.0000000000000465.

8. Hellmich B, Agueda A, Monti S, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020 Jan;79(1):19-30. doi: 10.1136/annrheumdis-2019-215672. Epub 2019 Jul 3.

9. Mainbourg S, Addario A, Samson M, et al. Prevalence of Giant Cell Arteritis Relapse in Patients Treated With Glucocorticoids: A MetaAnalysis. Arthritis Care Res (Hoboken). 2020 Jun;72(6):838-849. doi: 10.1002/acr.23901.

10. Monti S, Milanesi A, Klersy C, et al. Italian Society of Rheumatology Vasculitis Study Group. Age at diagnosis influences the clinical phenotype, treatment strategies and outcomes in patients with giant cell arteritis: results from the observational GCAGE study on a large cohort of 1004 patients. Ann Rheum Dis. 2023 Aug;82(8):1098-1106. doi: 10.1136/ard-2023-223895.

11. Maz M, Chung SA, Abril A, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis Rheumatol. 2021 Aug;73(8):1349-1365. doi: 10.1002/art.41774.

12. General characteristics of the drug olokizumab (Artlegia) LP LP-№ (008886)-(RG-RU) dated 11/12/2025.

13. Dejaco C, Ramiro S, Bond M, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update. Ann Rheum Dis. 2024 May 15;83(6):741-751. doi: 10.1136/ard-2023-224543.

14. Chrysidis S, Døhn UM, Terslev L, et al. Diagnostic accuracy of vascular ultrasound in patients with suspected giant cell arteritis (EUREKA): a prospective, multicentre, noninterventional, cohort study. Lancet Rheumatol. 2021 Dec;3(12):e865-e873. doi: 10.1016/S2665-9913(21)00246-0.

15. Ponte C, Grayson PC, Robson JC, et al; DCVAS Study Group. 2022 American College of Rheumatology/EULAR Classification Criteria for Giant Cell Arteritis. Arthritis Rheumatol. 2022 Dec;74(12):1881-1889. doi: 10.1002/art.42325.

16. Ho Lee Y, Gyu Song G. Comparison of the efficacy and safety of tocilizumab, sarilumab, and olokizumab in patients with active rheumatoid arthritis: a network meta-analysis of randomized controlled trials. Z Rheumatol. 2024 Feb;83(Suppl 1):97-106. doi: 10.1007/s00393-022-01315-0.

17. Nesher G. The diagnosis and classification of giant cell arteritis. J Autoimmun. 2014 Feb-Mar; 48-49:735. doi: 10.1016/j.jaut.2014.01.017.

18. Smetana GW, Shmerling RH. Does this patient have temporal arteritis? JAMA. 2002 Jan 2;287(1):92-101. doi: 10.1001/jama.287.1.92.

19. Evans JM, O'Fallon WM, Hunder GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann Intern Med. 1995 Apr 1;122(7):502-7. doi: 10.7326/0003-4819-122-7-199504010-00004.

20. Feist E, Fleischmann RM, Fatenejad S, et al. Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment. Modern Rheumatology Journal. 2024;18(6):21-35. (In Russ.). doi: 10.14412/1996-7012-2024-6-21-35.

21. Shesternya PA, Zagrebneva AI, Antipova OV, et al. Use of olokizumab, a direct interleukin 6 inhibitor, in the treatment of rheumatoid arthritis: real-world evidence. Modern Rheumatology Journal. 2025;19(2):39-49. (In Russ.). doi: 10.14412/1996-7012-2025-2-39-49.

22. Shesternya PA, Aitova EM, Alekseev EN, et al. Direct interleukin-6 blockade in real-world clinical practice – a path to rationalization of pharmacotherapy and control of rheumatoid arthritis. Modern Rheumatology Journal. 2026; 20(1):44-53. (In Russ.). doi: 10.14412/1996-7012-2026-1-44-53.

23. Stone JH, Tuckwell K, Dimonaco S, et al. Trial of Tocilizumab in Giant-Cell Arteritis. N Engl J Med. 2017 Jul 27;377(4):317-328. doi: 10.1056/NEJMoa1613849.